= Abstract = Testicular adrenal rest tumors are a well-known complication in male patients with congenital adrenal hyperplasia. Corticosteroid suppressive therapy usually results in the regression of these tumors. We describe a patient with 21-hydroxylase deficiency who developed bilateral testicular masses. Despite steroid suppressive therapy, the tumors did not regress and hormonal control was poor. Consequently, bilateral partial orchiectomies were performed. (Korean J Pediatr 2008;51:1018-1022 
Introduction
Congenital adrenal hyperplasia (CAH) is caused by an enzymatic defect in steroid biosynthesis in the adrenal cortex. 21-hydroxylase deficiency is the most common . In patients with 21-hydroxylase deficiency, precursor steroids, including 17-hydroxyprogesterone (17-OHP), accumulate and are diverted into the sex steroid pathway, resulting in increased androgen production 1) .
In CAH, testicular adrenal rest tumors (TARTs) are considered aberrant adrenal tissue that has descended with the testes and has become hyperplastic because of ACTH stimulation [2] [3] [4] . Microscopically, the tumors show features of steroid-producing tissue 5) . The growth of TARTs is stimulated by inadequate corticosteroid suppressive therapy and treatment with adequate doses of corticosteroids results in tumor regression 6) . Although the prevalence of TARTs in male children with 21-hydroxylase deficiency has been reported upto 24% 7) , there were a few reports of TARTs in Korean children with 21-hydroxylase deficiency 8, 9) .
We describe a TART in a Korean patient with 21-hydroxylase deficiency. The patient had bilateral testicular masses and bilateral partial orchiectomies were performed to remove the steroid-unresponsive testicular tumors. Pathology revealed a testicular adrenal rest tumor.
Case report
A 15-year-old boy was admitted with bilateral testicular masses. He weighed 3.31 kg at birth and presented with poor oral intake, vomiting, dehydration, lethargy, and electrolyte imbalance (hyponatremia and hyperkalemia) immediately after birth. His family history was unremarkable. He was initially treated with NaCl and fludrocortisone, based on a diagnosis of pseudohypoaldosteronism. He was diagnosed with the salt-wasting form of 21-hydroxylase deficiency at 1 year of age and was then treated with corticosteroid (dexamethasone or deflazacort) and fludrocortisone until 10 years of age.
At 10 years of age, he was transferred to our hospital for treatment of nail dysplasia and 21-hydroxylase deficiency.
On physical examination, his height was 133 cm (z score of -0.65), and weight was 30 kg (z score of -0.55). The phallus and pubic hair were both at Tanner stage II, and both testes were 3 mL in volume (Fig. 1, Table 1 ). Predicted adult height (PAH) calculated using the Bayley and Pinneau method was 156.5 cm. He was treated with oral (PO) deflazacort (5 mg) once daily (QD) and fludrocortisone (0.1 mg PO) QD. The plasma 17-OHP level was 55 ng/mL and bone age was compatible to 13 years of age. The elevated 17-OHP level and advanced bone age might result from poor com- After treatment for 5 months, the 17-OHP level and plasma renin activity (PRA) were 1.7 ng/mL (treatment target range, < 5 ng/mL) and > 20 ng/mL/hr (normal range, 0.5-3.3 ng/mL/hr), respectively. The fludrocortisone dosage was increased to 0.15 mg/day due to improper suppression of PRA. As the testicular volume increased to 4 mL despite the PAH of less than the 3rd percentile, daily growth hormone and monthly leuprolide actetate administration were started at doses with 4 IU/day and 1.88 mg/mo, respectively. At 13.4 years of age, GH and leuprolide treatment was discontinued as his bone age accelerated to 15 years. During 3 years of treatment, his height increased from 135.2 cm to 155.5 cm (mean growth velocity, 6.9 cm/yr) and testis size increased to 4 mL. One year after discontinuation of GH and leuprolide, we performed testicular and adrenal magnetic resonance imaging (MRI) because of the increase in testicular volume. Testicular MRI showed bilateral testicular adrenal rest tumor (right, 4.6× 2.8× 2.9 cm; left, 3.9× 3.0× 1.9 cm) with compressed normal testicular tissue at peripheral location (Fig. 2) . There was no definite mass in both adrenal glands. The serum 17-OHP level was 64 ng/mL and the PRA was 26.5 ng/mL/h. Alpha-fetoprotein, human choriogonadotropin, and lactate dehydrogenase levels were within normal ranges. We performed bilateral partial orchiectomies. Microscopic analysis revealed adrenal rest tumors containing tumor cell nests with fibrous bands, polygonal tumor cells with eosinophilic cytoplasms and focal lymphoid aggregates (Fig.   3) . Reinke crystalloids or mitotic activity was not observed.
These findings were consistent with the characteristics of adrenal rest tumors. One months after the partial orchiectomies, the volumes of both testes were 5 mL and the reduction in testis size was confirmed by ultrasonography. One Fig. 2 . Testicular magnetic resonance imaging shows bilateral testicular adrenal rest tumor (right, 4.6× 2.8× 2.9 cm; left, 3.9 × 3.0× 1.9 cm) with compressed normal testicular tissue at peripheral location. ; these lesions are often bilateral (83%). Concentrations of 17-OHP and androgen are usually elevated. In testicular ultrasonographs, these lesions present as hypoechoic infiltrative nodules and are usually located near the mediastinum testis 10) . TARTs have been detected even in childhood 7) , recommending that ulatrasonographic screening should begin no later than adolescence 1) . If TARTs are refractory to medical treatment, partial orchiectomy is recommended 11, 12) . . Adrenal rests within the testis occur in 7.5% 15% of neonates and normally regress in early infancy 7) . However, in CAH patients, it is believed that these cells may persist and proliferate with preservation of adrenal-like hormone production properties , as was the case with our patient. These observations suggest that surgical treatment may not be appropriate for improving hormonal control. TARTs may cause testicular tenderness and pain but these symptoms disappear after their removal 12) . Infertility and pituitarygonadal dysfunction may develop in male patients with 21-hydroxylase deficiency. First, sustained suppression of the pituitarygonadal axis by a high level of adrenal androgen secretion results in small testicular size and infertility 3, 6) . Second, TARTs may cause obstructive azospermia or oligospermia 12, 14, 15) . When large TARTs are located in the mediastinum testis proximal to the epididymis, . If there is no response, tumor enucleation or partial orchiectomy may be performed to preserve fertility 5, 11, 12, 15, 16) . The fertility prognosis of TART patients is uncertain. If irreversible testicular damage caused by longstanding obstruction of the seminiferous tubules is present prior to tumor removal, testicular function cannot be restored by surgery 12) .
TARTs
To our knowledge, this is the third report of a TART in Korea 8, 9) . In the first case reported by Kim and Han 8) , contrary to our case, the patient was diagnosed with CAH after removal of TART. And in the second case reported by Cho et al. 9) , TART accompanied with adrenal incidentaloma was not decreased with intense hydrocortiosne suppression therapy. Our 21-hydroxylase-deficient patient received corticosteroid suppressive treatment since infancy. The parents reported good drug compliance but we think that the patient did not receive sufficient glucocorticoid and fludrocortisone considering his bone age advancement, short PAH, high level of 17-OHP and sexual maturation at an inappropriately young chronological age. Bilateral testicular masses developed 1 year after discontinuation of GH treatment. We do not know what effect the GH had on the development of the TART. Because of unresponsiveness to medical treatment over a period of 1 year, bilateral partial orchiectomies was performed. Despite the operation, levels of 17-OHP and PRA remained high. We plan to study the patient' s pituitarygonadal function and fertility when he is 18 years of age.
We recommend periodic testicular ultrasonography for adolescents with CAH because it enables small testicular lesions to be detected at an early age and facilitates early treatment, which may prevent irreversible testicular damage. 
